Using modified CAR-T cells to treat head and neck cancer
iC9-CAR.CSPG4 CAR-T Cells for Head and Neck Squamous Cell Carcinoma
This study is testing a new treatment using specially modified immune cells to help patients with head and neck cancer that hasn't responded to regular treatments, and it aims to see how well these cells can fight the cancer and how safe they are.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11029590 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have not responded to standard therapies. The study involves using CAR-T cells that target a specific protein, CSPG4, which is overexpressed in these tumors. Patients will receive these modified T cells in a controlled setting, and researchers will monitor their safety and effectiveness through various tests, including biopsies and blood samples. The goal is to understand how these CAR-T cells interact with the cancer and the immune system over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with recurrent or metastatic head and neck squamous cell carcinoma who have not responded to previous treatments.
Not a fit: Patients with early-stage head and neck cancer or those who have not yet undergone standard therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with advanced head and neck cancer.
How similar studies have performed: Other research has shown promising results with CAR-T cell therapies in various cancers, indicating potential for success with this approach in HNSCC.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Weiss, Jared — Univ of North Carolina Chapel Hill
- Study coordinator: Weiss, Jared
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.